Related Experiment Videos
Methotrexate as relapse therapy for rhabdomyosarcoma
The American Journal of Pediatric Hematology/Oncology
|January 1, 1986
Summary
High-dose, 42-hour methotrexate (MTX) infusions show promise for rhabdomyosarcoma relapse. This intensive chemotherapy regimen led to significant responses in all treated patients.
Area of Science:
- Pediatric Oncology
- Medical Chemotherapy
Background:
- Rhabdomyosarcoma is a common childhood cancer.
- Local relapse after standard therapy presents a significant challenge.
Observation:
- Four patients with relapsed rhabdomyosarcoma received high-dose, 42-hour methotrexate infusions.
- Treatment response was evaluated based on remission status.
Findings:
- All four patients demonstrated a positive response to the high-dose methotrexate therapy.
- One patient achieved a complete remission, and two patients achieved a partial remission.
Implications:
- Long-duration methotrexate infusions may be a valuable component of combination chemotherapy for relapsed rhabdomyosarcomas.
- Further research into intensive methotrexate regimens for pediatric sarcoma relapse is warranted.